实物展示:美敦力 冠脉 Resolute Integrity Zotarolimus-Eluting Coronary Stent System 药物洗脱冠脉支架系统
规格:
型号 | 直径 | 长度 | 型号 | 直径 | 长度 | |
RSINT22508X | 2.25 | 8 | RSINT22522X | 2.25 | 22 | |
RSINT25008X | 2.5 | 8 | RSINT25022X | 2.5 | 22 | |
RSINT27508X | 2.75 | 8 | RSINT27522X | 2.75 | 22 | |
RSINT30009X | 3 | 9 | RSINT30022X | 3 | 22 | |
RSINT35009X | 3.5 | 9 | RSINT35022X | 3.5 | 22 | |
RSINT40009X | 4 | 9 | RSINT40022X | 4 | 22 | |
RSINT22512X | 2.25 | 12 | RSINT22526X | 2.25 | 26 | |
RSINT25012X | 2.5 | 12 | RSINT25026X | 2.5 | 26 | |
RSINT27512X | 2.75 | 12 | RSINT27526X | 2.75 | 26 | |
RSINT30012X | 3 | 12 | RSINT30026X | 3 | 26 | |
RSINT35012X | 3.5 | 12 | RSINT35026X | 3.5 | 26 | |
RSINT40012X | 4 | 12 | RSINT40026X | 4 | 26 | |
RSINT22514X | 2.25 | 14 | RSINT22530X | 2.25 | 30 | |
RSINT25014X | 2.5 | 14 | RSINT25030X | 2.5 | 30 | |
RSINT27514X | 2.75 | 14 | RSINT27530X | 2.75 | 30 | |
RSINT30015X | 3 | 15 | RSINT30030X | 3 | 30 | |
RSINT35015X | 3.5 | 15 | RSINT35030X | 3.5 | 30 | |
RSINT40015X | 4 | 15 | RSINT40030X | 4 | 30 | |
RSINT22518X | 2.25 | 18 | RSINT30034X | 3 | 34 | |
RSINT25018X | 2.5 | 18 | RSINT35034X | 3.5 | 34 | |
RSINT27518X | 2.75 | 18 | RSINT40034X | 4 | 34 | |
RSINT30018X | 3 | 18 | RSINT30038X | 3 | 38 | |
RSINT35018X | 3.5 | 18 | RSINT35038X | 3.5 | 38 | |
RSINT40018X | 4 | 18 | RSINT40038X | 4 | 38 |
商务合作可与我司商务经理联系
微信同号:朱经理17137860108 许经理 18664509979 固话020-32641702
产品名称
药物洗脱冠脉支架系统 Resolute Integrity Zotarolimus-Eluting Coronary Stent System
结构及组成/主要组成成分
该产品由药物洗脱支架和MicroTrac 快速交换型输送系统组成。药物洗脱支架由金属支架、底涂层和药物涂层组成;金属支架由35NLT钴铬合金制成;底涂层由Parylene C制成;药物涂层由唑他莫司(Zotarolimus)和BioLinx聚合物(C10/C19/PVP)构成,药物剂量为1.6μg/mm2,支架总药量为59-380μg。输送系统导管的有效工作长度为140厘米,输送系统可兼容最大外径为0.36 mm(0.014英寸)的导丝和最小1.42mm(0.056英寸,5F)的导引导管。环氧乙烷灭菌,一
适用范围/预期用途
该产品预期适用于符合进行经皮腔内冠状动脉成形术 (PTCA)、参考血管直径为 2.25 mm 到 4.0 mm 和病变长度≤27mm的患者。该产品在冠状动脉介入治疗中用于扩大冠状动脉腔直径,减少再狭窄。 此支架为永久性植入器械。
注册证编号
国械注进20163460682